Liu, Y. 2024. How do varying concentrations and treatment durations of anti-PDL1 antibodies affect HCT116 cell viability, xenograft tumor size, and T cell activation, as measured by MTT assay, tumor weight, and IL-2 production, respectively?. MedScien. 2, 6 (Dec. 2024), 2912. DOI:https://doi.org/10.61173/n49rc157.